Skip to search formSkip to main contentSkip to account menu

APG101

Known as: CD95 ECD/IgG-Fc Fusion Protein APG101 
A human, soluble fusion protein consisting of the extracellular domain of the CD95 receptor fused to the Fc-domain of the human IgG antibody, with… 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (3)

CD95 AntigensImmunoglobulin GRecombinant Fusion Proteins
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Abstract 464: Methylation of a single CpG site in the CD95-ligand promoter is a biomarker predicting the response to therapy with APG101 in glioblastoma
2016
2016
APG101 efficiently rescues erythropoiesis in lower risk myelodysplastic syndromes with severe impairment of hematopoiesis
CD95, a member of the death receptor family initiates a caspase-dependent apoptosis, when activated by its ligand CD95L, thought… 
Review
2015
Review
2015
Abstract A115: The CD95 ligand inhibitor APG 101 reduces tumor recurrence and metastasis in an adjuvant orthotopic mouse model of pancreatic cancer as well as primary tumor load in a palliative…
Since the first description of CD95/Fas this member of the death receptor superfamily has been regarded as paradigmatic for death… 
2014
2014
Cancer Therapy : Clinical A Phase II , Randomized , Study of Weekly APG 101 þ Reirradiation versus Reirradiation in Progressive Glioblastoma
Purpose: Preclinical data indicate anti-invasive activity of APG101, a CD95 ligand (CD95L)–binding fusion protein, in… 
2010
2010
Abstract LB-273: Inhibition of CD95-dependent signaling for the treatment of glioblastoma multiforme
CD95 (APO-1/FAS) is a receptor that belongs to the Tumor Necrosis Factor Super Family (TNFSF). Binding of the cognate ligand… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)